#USA #Chicago #OncoHost #NSCLC #AACR

OncoHost Unveils Groundbreaking Research at AACR 2025

OncoHost, a leading technology company in precision medicine, has made significant strides in cancer research by focusing on plasma proteomics. In a recent announcement, the company revealed its acceptance to present at the American Association for Cancer Research (AACR) Annual Meeting 2025, set to take place from April 25 to 30 in Chicago, Illinois. Their presentation will spotlight the groundbreaking research regarding advanced treatment strategies for non-small cell lung cancer (NSCLC), particularly those treated with immune checkpoint inhibitors.

Understanding the Research

The poster presentation, titled "Clinical and Biological Implications of Plasma Proteomic Patterns in NSCLC Patients Treated with Immune Checkpoint Inhibitors," dives deep into the intricate world of plasma proteins. Key findings stem from their proprietary model, PROphetNSCLC™, which is designed to aid in treatment decision-making for patients suffering from advanced stages of NSCLC. This innovative study represents a collaborative effort involving esteemed institutions such as The Ohio State University, UC Davis, and Baylor University Medical Center.

Breaking Down the Findings

Dr. Michal Harel, OncoHost’s Director of Science and Innovation, emphasizes the value of this research in understanding the biological mechanisms that lead to immunotherapy resistance in NSCLC patients. The analysis centered on resistance-associated proteins (RAPs), which reveal significant insights into patient stratification and potential new therapeutic targets. Dr. Harel stated, "Our analysis identifies key proteomic signatures that inform both clinical outcomes and patient stratification, and can aid in discovering new therapeutic targets."

Through extensive data collection, the research team identified five distinct proteomic expression patterns, indicating varying responses to immunotherapy between healthy individuals and NSCLC patients. These findings exposed underlying mechanisms of treatment resistance, shedding light on processes like angiogenesis, immune modulation, and chemoresistance. Impressively, the study also noted that 17.5% of the identified RAPs are targetable with existing or investigational drugs, opening new avenues for therapeutic interventions.

Impacts on the Future of Cancer Treatment

Ofer Sharon, MD, the CEO of OncoHost, expresses his pride in the opportunity to present at AACR, highlighting the importance of comprehension of treatment resistance in the evolving landscape of precision medicine. He notes, "We are transitioning from solely predictive diagnostics to a more comprehensive approach that explores the underlying reasons for treatment resistance. Our research propels us closer to unlocking the full potential of proteomics in oncology."

Presentation Details

• - Title: Clinical and Biological Implications of Plasma Proteomic Patterns in NSCLC Patients Treated with Immune Checkpoint Inhibitors
• - Session Title: Predictive Biomarkers 3
• - Poster Board: 27
• - Presenter: Michal Harel, PhD
• - Date & Time: April 28, 2025, from 9:00 AM to 12:00 PM CDT

The abstract of this significant work is available on the AACR website for those wishing to explore the research further.

About OncoHost

OncoHost, headquartered in Binyamina, Israel, and Cary, North Carolina, is at the forefront of transforming precision medicine to enhance patient outcomes significantly. Their innovative platform, PROphet®, leverages plasma-based proteomic pattern analysis to refine first-line immunotherapy decision-making. Currently, the PROphetNSCLC™ test aids physicians in discerning optimal treatment protocols for individual patients, which can significantly affect their overall survival rates.

Bolstered by a strong clinical trial infrastructure that spans over 40 sites and encompasses 1,700 patients globally, OncoHost stands poised to lead transformative advancements in precision diagnostics and biomarker development.

For further information about their pioneering efforts, visit OncoHost's official website.